Clinical activity of the oral ALK and MET inhibitor PF-02341066 in non-small lung cancer (NSCLC) with EML4-ALK translocations

被引：0
|
作者：
Shaw, Alice T. [2 ]
Costa, Daniel B. [1 ]
Iafrate, A. J. [2 ]
Dezube, Bruce J. [1 ]
Shapiro, Geoffrey, I [4 ]
Bang, Yung J. [7 ]
Janne, Pasi A. [4 ]
Lynch, Thomas J. [2 ]
Maki, Robert G. [5 ]
Camidge, D. R. [3 ]
Solomon, Benjamin [6 ]
Kwak, Eunice L. [2 ]
Tan, Weiwei [10 ]
Chen, Isan [10 ]
Christensen, Jamie [10 ]
Wilner, Keith [9 ]
Clark, Jeffrey W. [2 ]
Salgia, Ravi [8 ]
机构：
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA
[2] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA
[3] Univ Colorado, Ctr Canc, Denver, CO 80262 USA
[4] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[6] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[7] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[8] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[9] Pfizer Pharmaceut Inc, La Jolla, CA USA
[10] Pfizer Inc, La Jolla, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S305 / S306
页数：2
相关论文
共 50 条
  • [1] Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC)
    Bang, Y.
    Kwak, E. L.
    Shaw, A. T.
    Camidge, D. R.
    Iafrate, A. J.
    Maki, R. G.
    Solomon, B. J.
    Ou, S. I.
    Salgia, R.
    Clark, J. W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [2] CLINICAL ACTIVITY OF CRIZOTINIB (PF-02341066), IN ALK-POSITIVE PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)
    Camidge, D. R.
    Bang, Y.
    Iafrate, A. J.
    Kwak, E. L.
    Maki, R. G.
    Solomon, B.
    Ou, S. I.
    Salgia, R.
    Shaw, A.
    Clark, J.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 123 - 123
  • [3] ALK Inhibitor PF02341066 (Crizotinib) Increases Sensitivity to Radiation in Non-Small Cell Lung Cancer Expressing EML4-ALK
    Sun, Yunguang
    Nowak, Kamila A.
    Zaorsky, Nicholas G.
    Winchester, Chia-Lin
    Dalal, Kunal
    Giacalone, Nicholas J.
    Liu, Ningbo
    Werner-Wasik, Maria
    Wasik, Mariusz A.
    Dicker, Adam P.
    Lu, Bo
    [J]. MOLECULAR CANCER THERAPEUTICS, 2013, 12 (05) : 696 - 704
  • [4] Antitumor efficacy of crizotinib (PF-02341066), a potent and selective ALK and c-Met RTK inhibitor, in EML4-ALK driven NSCLC tumors in vitro and in vivo
    Zou, Helen Y.
    Li, Qiuhua
    Lee, Joseph
    Engstrom, Lars
    Lu, Melissa West
    Young, Alex
    Timofeevski, Sergei
    Dinh, Dac M.
    Yamazaki, Shinji
    Lam, Justine
    Feng, Zheng
    Nickel, Jeffrey
    Lappin, Patrick B.
    Nichols, Tim
    Wong, Anthony
    Snider, Brittany
    Gukasyan, Hovhannes
    Bender, Steve
    Zabludoff, Sonya
    Smeal, Tod
    Christensen, James R.
    [J]. CANCER RESEARCH, 2011, 71
  • [5] Targeting EML4-ALK driven non-small cell lung cancer (NSCLC)
    Moran, Teresa
    Quiroga, Vanesa
    Llanos Gil, Maria de Los
    Vila, Laia
    Pardo, Nuria
    Carcereny, Enric
    Capdevila, Laia
    Munoz-Marmol, Ana M.
    Rosell, Rafael
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2013, 2 (02) : 128 - 141
  • [6] Frequency and clinical relevance of EGFR mutations and EML4-ALK translocations in octogenarians with non-small cell lung cancer
    Tufman, Amanda
    Kahnert, Kathrin
    Duell, Thomas
    Kauffmann-Guerrero, Diego
    Milger, Katrin
    Schneider, Christian
    Stump, Julia
    Syunyaeva, Zulfiya
    Huber, Rudolf Maria
    Reu, Simone
    [J]. ONCOTARGETS AND THERAPY, 2017, 10 : 5179 - 5186
  • [7] Clinical Outcomes and ALK Resistance Mutations in ALK plus Non-Small Cell Lung Cancer According to EML4-ALK Variant
    Lin, J.
    Zhu, V.
    Yoda, S.
    Yeap, B.
    Jessop, N.
    Schrock, A.
    Dagogo-Jack, I.
    Gowen, K.
    Stephens, P. J.
    Ross, J.
    Ali, S.
    Miller, V.
    Gainor, J.
    Hata, A.
    Iafrate, A.
    Ou, S.
    Shaw, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1828 - S1828
  • [8] Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066
    Kwak, E. L.
    Camidge, D. R.
    Clark, J.
    Shapiro, G. I.
    Maki, R. G.
    Ratain, M. J.
    Solomon, B.
    Bang, Y.
    Ou, S.
    Salgia, R.
    [J]. EJC SUPPLEMENTS, 2009, 7 (03): : 8 - 8
  • [9] Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066
    Kwak, E. L.
    Camidge, D. R.
    Clark, J.
    Shapiro, G. I.
    Maki, R. G.
    Ratain, M. J.
    Solomon, B.
    Bang, Y.
    Ou, S.
    Salgia, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] The biology and treatment of EML4-ALK non-small cell lung cancer
    Sasaki, Takaaki
    Rodig, Scott J.
    Chirieac, Lucian R.
    Janne, Pasi A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2010, 46 (10) : 1773 - 1780
12345